AU2012332111B2 - Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia - Google Patents

Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia Download PDF

Info

Publication number
AU2012332111B2
AU2012332111B2 AU2012332111A AU2012332111A AU2012332111B2 AU 2012332111 B2 AU2012332111 B2 AU 2012332111B2 AU 2012332111 A AU2012332111 A AU 2012332111A AU 2012332111 A AU2012332111 A AU 2012332111A AU 2012332111 B2 AU2012332111 B2 AU 2012332111B2
Authority
AU
Australia
Prior art keywords
compound
cells
catenin
beta
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012332111A
Other languages
English (en)
Other versions
AU2012332111A1 (en
Inventor
Kapil N. Bhalla
Stephen Horrigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Cat Pharmaceuticals LLC
Original Assignee
Beta Cat Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Cat Pharmaceuticals LLC filed Critical Beta Cat Pharmaceuticals LLC
Publication of AU2012332111A1 publication Critical patent/AU2012332111A1/en
Application granted granted Critical
Publication of AU2012332111B2 publication Critical patent/AU2012332111B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012332111A 2011-11-06 2012-11-06 Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia Active AU2012332111B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556245P 2011-11-06 2011-11-06
US61/556,245 2011-11-06
PCT/US2012/063746 WO2013067547A1 (en) 2011-11-06 2012-11-06 METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA

Publications (2)

Publication Number Publication Date
AU2012332111A1 AU2012332111A1 (en) 2014-05-22
AU2012332111B2 true AU2012332111B2 (en) 2016-11-17

Family

ID=48192926

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012332111A Active AU2012332111B2 (en) 2011-11-06 2012-11-06 Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia

Country Status (15)

Country Link
US (1) US9238030B2 (enExample)
EP (1) EP2773607B1 (enExample)
JP (1) JP6063472B2 (enExample)
KR (1) KR102336767B1 (enExample)
CN (1) CN103917514B (enExample)
AU (1) AU2012332111B2 (enExample)
BR (1) BR112014010584A2 (enExample)
CA (1) CA2853491C (enExample)
EA (1) EA027770B1 (enExample)
ES (1) ES2624427T3 (enExample)
IL (1) IL232452A (enExample)
MX (1) MX354653B (enExample)
SG (1) SG11201402056XA (enExample)
WO (1) WO2013067547A1 (enExample)
ZA (1) ZA201403003B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3328819B1 (en) * 2015-07-28 2020-04-01 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compounds prodrugs and their uses
US9963475B2 (en) * 2015-07-28 2018-05-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
WO2019229001A1 (en) * 2018-05-30 2019-12-05 Otto-Von-Guericke-Universität Magdeburg Compounds for the treatment of jak2-v617f-associated cmn
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147713A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
WO2010059142A1 (en) * 2008-11-21 2010-05-27 Avalon Pharmaceuticals Anthraquinone dioximes and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101486026B1 (ko) * 2007-05-10 2015-01-22 도그우드 파마슈티컬스, 아이엔씨. 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도
BR112012002942A2 (pt) * 2009-08-10 2015-10-13 Epitherix Llc indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes.
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
CN102665756A (zh) * 2009-10-01 2012-09-12 Csl有限公司 费城染色体阳性白血病的治疗方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147713A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
WO2010059142A1 (en) * 2008-11-21 2010-05-27 Avalon Pharmaceuticals Anthraquinone dioximes and uses thereof

Also Published As

Publication number Publication date
EP2773607A4 (en) 2015-03-11
EP2773607A1 (en) 2014-09-10
CA2853491C (en) 2019-12-10
CN103917514A (zh) 2014-07-09
HK1198440A1 (en) 2015-04-24
US20130143920A1 (en) 2013-06-06
KR20140089418A (ko) 2014-07-14
EA201490937A1 (ru) 2014-08-29
US9238030B2 (en) 2016-01-19
CA2853491A1 (en) 2013-05-10
ZA201403003B (en) 2017-08-30
IL232452A0 (en) 2014-06-30
AU2012332111A1 (en) 2014-05-22
JP6063472B2 (ja) 2017-01-18
CN103917514B (zh) 2016-11-16
IL232452A (en) 2017-01-31
SG11201402056XA (en) 2014-10-30
MX354653B (es) 2018-03-07
EA027770B1 (ru) 2017-08-31
KR102336767B1 (ko) 2021-12-10
JP2014534229A (ja) 2014-12-18
MX2014005498A (es) 2016-05-05
BR112014010584A2 (pt) 2017-05-02
NZ624446A (en) 2016-01-29
EP2773607B1 (en) 2017-03-29
KR102336767B9 (ko) 2025-01-08
ES2624427T3 (es) 2017-07-14
WO2013067547A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
CA2853491C (en) Methods for treatment of diseases and disorders related to transducin .beta.-like protein 1 (tbl1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
US12208097B2 (en) Protein kinase C inhibitors for treatment of uveal melanoma
HK1251162A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
JP2019518048A (ja) がんの予防および／または治療のための化合物、組成物および方法
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
SG194047A1 (en) Combinations of akt and mek inhibitor compounds, and methods of use
CN112912075B (zh) 治疗前列腺癌的组合疗法
EP3638690A1 (en) Methods to treat gliomas using a stat3 inhibitor
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
HK1198440B (en) Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
NZ624446B2 (en) Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US9907797B2 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
JP2020083849A (ja) ガンを治療又は予防するための医薬組成物
WO2023224961A1 (en) Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
HK1253277B (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)